{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:45:49Z","timestamp":1793295949148,"version":"4.5.0"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05424-0","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:43:34Z","timestamp":1764585814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in Alzheimer\u2019s Disease: Recent Advances and Controversies"],"prefix":"10.1007","volume":"63","author":[{"given":"Lingling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"10248","key":"5424_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England) 396(10248):413\u2013446","journal-title":"Lancet (London, England)"},{"key":"5424_CR2","doi-asserted-by":"crossref","unstructured":"(2024) Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association 20(5):3708-3821","DOI":"10.1002\/alz.13809"},{"issue":"2","key":"5424_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1474-4422(22)00529-4","volume":"22","author":"S Mead","year":"2023","unstructured":"Mead S, Fox NC (2023) Lecanemab slows Alzheimer\u2019s disease: hope and challenges. Lancet Neurol 22(2):106\u2013108","journal-title":"Lancet Neurol"},{"issue":"20","key":"5424_CR4","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC (2023) Alzheimer\u2019s disease: from immunotherapy to immunoprevention. Cell 186(20):4260\u20134270","journal-title":"Cell"},{"issue":"6","key":"5424_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"key":"5424_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203","volume":"94","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W (2024) Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ageing Res Rev 94:102203","journal-title":"Ageing Res Rev"},{"issue":"7","key":"5424_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","volume":"80","author":"DB Rosoff","year":"2022","unstructured":"Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW (2022) Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol 80(7):653\u2013662","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5424_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A (2022) The multifaceted biology of PCSK9. Endocr Rev 43(3):558\u2013582","journal-title":"Endocr Rev"},{"issue":"2","key":"5424_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154\u2013156","journal-title":"Nat Genet"},{"issue":"12","key":"5424_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41556-021-00805-8","volume":"23","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Jeppesen DK, Higginbotham JN, Graves-Deal R, Trinh VQ, Ramirez MA et al (2021) Supermeres are functional extracellular nanoparticles replete with disease biomarkers and therapeutic targets. Nat Cell Biol 23(12):1240\u20131254","journal-title":"Nat Cell Biol"},{"issue":"10","key":"5424_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.jacbts.2023.06.005","volume":"8","author":"C Matyas","year":"2023","unstructured":"Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A et al (2023) PCSK9, a promising novel target for age-related cardiovascular dysfunction. JACC Basic Transl Sci 8(10):1334\u20131353","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"5424_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37(2):161\u2013165","journal-title":"Nat Genet"},{"issue":"9","key":"5424_CR13","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1194\/jlr.M006635","volume":"51","author":"M Liu","year":"2010","unstructured":"Liu M, Wu G, Baysarowich J, Kavana M, Addona GH, Bierilo KK et al (2010) PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res 51(9):2611\u20132618","journal-title":"J Lipid Res"},{"issue":"7","key":"5424_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100339","volume":"3","author":"N DeForest","year":"2023","unstructured":"DeForest N, Kavitha B, Hu S, Isaac R, Krohn L, Wang M et al (2023) Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins. Cell Genom 3(7):100339","journal-title":"Cell Genom"},{"key":"5424_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbi.2023.11.008","volume":"115","author":"A Vilella","year":"2024","unstructured":"Vilella A, Bodria M, Papotti B, Zanotti I, Zimetti F, Remaggi G et al (2024) PCSK9 ablation attenuates A\u03b2 pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice. Brain Behav Immun 115:517\u2013534","journal-title":"Brain Behav Immun"},{"issue":"1","key":"5424_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/ATVBAHA.121.316902","volume":"42","author":"Y Guo","year":"2022","unstructured":"Guo Y, Tang Z, Yan B, Yin H, Tai S, Peng J et al (2022) PCSK9 (proprotein convertase subtilisin\/kexin type 9) triggers vascular smooth muscle cell senescence and apoptosis: implication of its direct role in degenerative vascular disease. Arterioscler Thromb Vasc Biol 42(1):67\u201386","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"5424_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S2213-8587(22)00254-6","volume":"10","author":"RA Hegele","year":"2022","unstructured":"Hegele RA (2022) Pcsk9 inhibition in children with familial hypercholesterolaemia. Lancet Diabetes Endocrinol 10(10):686\u2013688","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"5424_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S et al (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100(3):928\u2013933","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"5424_CR19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","volume":"132","author":"N Bergeron","year":"2015","unstructured":"Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM (2015) Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132(17):1648\u20131666","journal-title":"Circulation"},{"issue":"16","key":"5424_CR20","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A et al (2023) Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol 81(16):1553\u20131564","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5424_CR21","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1073\/pnas.0712064105","volume":"105","author":"HJ Kwon","year":"2008","unstructured":"Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 105(6):1820\u20131825","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5424_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jmb.2004.10.050","volume":"345","author":"S Henrich","year":"2005","unstructured":"Henrich S, Lindberg I, Bode W, Than ME (2005) Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 345(2):211\u2013227","journal-title":"J Mol Biol"},{"issue":"11","key":"5424_CR23","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI29383","volume":"116","author":"TA Lagace","year":"2006","unstructured":"Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB et al (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116(11):2995\u20133005","journal-title":"J Clin Invest"},{"issue":"37","key":"5424_CR24","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.0703402104","volume":"104","author":"EN Hampton","year":"2007","unstructured":"Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G (2007) The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A 104(37):14604\u201314609","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5424_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nsmb1235","volume":"14","author":"D Cunningham","year":"2007","unstructured":"Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA et al (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14(5):413\u2013419","journal-title":"Nat Struct Mol Biol"},{"issue":"47","key":"5424_CR26","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W et al (2004) NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279(47):48865\u201348875","journal-title":"J Biol Chem"},{"issue":"23","key":"5424_CR27","doi-asserted-by":"publisher","first-page":"19266","DOI":"10.1074\/jbc.M112.363382","volume":"287","author":"V Sharotri","year":"2012","unstructured":"Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM (2012) Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin\/kexin type 9 (PCSK9). J Biol Chem 287(23):19266\u201319274","journal-title":"J Biol Chem"},{"issue":"8","key":"5424_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.bbalip.2010.05.009","volume":"1801","author":"MA Wollmer","year":"2010","unstructured":"Wollmer MA (2010) Cholesterol-related genes in Alzheimer\u2019s disease. Biochim Biophys Acta 1801(8):762\u2013773","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"5424_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11883-022-01057-z","volume":"24","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Gar\u00e7on D (2022) Expanding biology of PCSK9: roles in atherosclerosis and beyond. Curr Atheroscler Rep 24(10):821\u2013830","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"5424_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/joim.13577","volume":"293","author":"M Abifadel","year":"2023","unstructured":"Abifadel M, Boileau C (2023) Genetic and molecular architecture of familial hypercholesterolemia. J Intern Med 293(2):144\u2013165","journal-title":"J Intern Med"},{"issue":"7","key":"5424_CR31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1194\/jlr.M014118","volume":"52","author":"E Rousselet","year":"2011","unstructured":"Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten ME, Prat A et al (2011) PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 52(7):1383\u20131391","journal-title":"J Lipid Res"},{"issue":"4","key":"5424_CR32","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N et al (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283(4):2363\u20132372","journal-title":"J Biol Chem"},{"key":"5424_CR33","doi-asserted-by":"publisher","first-page":"1084633","DOI":"10.3389\/fnmol.2022.1084633","volume":"15","author":"A P\u00e4rn","year":"2022","unstructured":"P\u00e4rn A, Olsen D, Tuvikene J, Kaas M, Borisova E, Bilgin M et al (2022) PCSK9 deficiency alters brain lipid composition without affecting brain development and function. Front Mol Neurosci 15:1084633","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"5424_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"J Kim","year":"2009","unstructured":"Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V et al (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64(5):632\u2013644","journal-title":"Neuron"},{"issue":"8","key":"5424_CR35","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.neurobiolaging.2014.02.005","volume":"35","author":"N Fabelo","year":"2014","unstructured":"Fabelo N, Mart\u00edn V, Mar\u00edn R, Moreno D, Ferrer I, D\u00edaz M (2014) Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer\u2019s disease and facilitates APP\/BACE1 interactions. Neurobiol Aging 35(8):1801\u20131812","journal-title":"Neurobiol Aging"},{"issue":"8","key":"5424_CR36","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ajpath.2019.04.010","volume":"189","author":"T Bilousova","year":"2019","unstructured":"Bilousova T, Melnik M, Miyoshi E, Gonzalez BL, Poon WW, Vinters HV et al (2019) Apolipoprotein E\/amyloid-\u03b2 complex accumulates in Alzheimer disease cortical synapses via apolipoprotein E receptors and is enhanced by APOE4. Am J Pathol 189(8):1621\u20131636","journal-title":"Am J Pathol"},{"issue":"7","key":"5424_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/hmg\/ddm365","volume":"17","author":"F Zou","year":"2008","unstructured":"Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, Simpson JF et al (2008) Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer\u2019s disease. Hum Mol Genet 17(7):929\u2013935","journal-title":"Hum Mol Genet"},{"issue":"3","key":"5424_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neures.2007.07.004","volume":"59","author":"M Mulder","year":"2007","unstructured":"Mulder M, Koopmans G, Wassink G, Al Mansouri G, Simard ML, Havekes LM et al (2007) LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res 59(3):251\u2013256","journal-title":"Neurosci Res"},{"key":"5424_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1476-511X-13-175","volume":"13","author":"SH Wang","year":"2014","unstructured":"Wang SH, Huang Y, Yuan Y, Xia WQ, Wang P, Huang R (2014) LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses. Lipids Health Dis 13:175","journal-title":"Lipids Health Dis"},{"issue":"4","key":"5424_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neuron.2014.08.005","volume":"83","author":"C Lane-Donovan","year":"2014","unstructured":"Lane-Donovan C, Philips GT, Herz J (2014) More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 83(4):771\u2013787","journal-title":"Neuron"},{"issue":"50","key":"5424_CR41","doi-asserted-by":"publisher","first-page":"17068","DOI":"10.1523\/JNEUROSCI.4067-10.2010","volume":"30","author":"Q Liu","year":"2010","unstructured":"Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J et al (2010) Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci 30(50):17068\u201317078","journal-title":"J Neurosci"},{"issue":"7","key":"5424_CR42","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/cvr\/cvz338","volume":"116","author":"C Mineo","year":"2020","unstructured":"Mineo C (2020) Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res 116(7):1254\u20131274","journal-title":"Cardiovasc Res"},{"key":"5424_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fnagi.2014.00093","volume":"6","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Bu G (2014) The low-density lipoprotein receptor-related protein 1 and amyloid-\u03b2 clearance in Alzheimer\u2019s disease. Front Aging Neurosc 6:93","journal-title":"Front Aging Neurosc"},{"issue":"6","key":"5424_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0092-8674(00)80782-5","volume":"97","author":"M Trommsdorff","year":"1999","unstructured":"Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J et al (1999) Reeler\/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97(6):689\u2013701","journal-title":"Cell"},{"issue":"2","key":"5424_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0896-6273(00)80860-0","volume":"24","author":"G D'Arcangelo","year":"1999","unstructured":"D\u2019Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T (1999) Reelin is a ligand for lipoprotein receptors. Neuron 24(2):471\u2013479","journal-title":"Neuron"},{"key":"5424_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102339","volume":"98","author":"LX Yi","year":"2024","unstructured":"Yi LX, Zeng L, Wang Q, Tan EK, Zhou ZD (2024) Reelin links apolipoprotein E4, tau, and amyloid-\u03b2 in Alzheimer\u2019s disease. Ageing Res Rev 98:102339","journal-title":"Ageing Res Rev"},{"issue":"7673","key":"5424_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549(7673):523\u2013527","journal-title":"Nature"},{"issue":"4","key":"5424_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/1097-0029(20000815)50:4<273::AID-JEMT4>3.0.CO;2-0","volume":"50","author":"N Helbecque","year":"2000","unstructured":"Helbecque N, Amouyel P (2000) Very low density lipoprotein receptor in Alzheimer disease. Microsc Res Tech 50(4):273\u2013277","journal-title":"Microsc Res Tech"},{"issue":"3","key":"5424_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2(3):a006312","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"5424_CR50","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB et al (2008) ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118(12):4002\u20134013","journal-title":"J Clin Invest"},{"issue":"1","key":"5424_CR51","first-page":"1","volume":"117","author":"J Llorca","year":"2008","unstructured":"Llorca J, Rodr\u00edguez-Rodr\u00edguez E, Dierssen-Sotos T, Delgado-Rodr\u00edguez M, Berciano J, Combarros O (2008) Meta-analysis of genetic variability in the beta-amyloid production, aggregation and degradation metabolic pathways and the risk of Alzheimer\u2019s disease. Acta Neurol Scand 117(1):1\u201314","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"5424_CR52","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","volume":"69","author":"K Kysenius","year":"2012","unstructured":"Kysenius K, Muggalla P, M\u00e4tlik K, Arum\u00e4e U, Huttunen HJ (2012) PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 69(11):1903\u20131916","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"5424_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41589-022-01033-3","volume":"18","author":"Z Li","year":"2022","unstructured":"Li Z, Ferguson L, Deol KK, Roberts MA, Magtanong L, Hendricks JM et al (2022) Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat Chem Biol 18(7):751\u2013761","journal-title":"Nat Chem Biol"},{"issue":"2","key":"5424_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"5424_CR55","first-page":"746","volume":"5","author":"JE Vance","year":"2012","unstructured":"Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 5(6):746\u2013755","journal-title":"Dis Model Mech"},{"issue":"384","key":"5424_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaa6674","volume":"8","author":"C Lane-Donovan","year":"2015","unstructured":"Lane-Donovan C, Philips GT, Wasser CR, Durakoglugil MS, Masiulis I, Upadhaya A et al (2015) Reelin protects against amyloid \u03b2 toxicity in vivo. Sci Signal 8(384):ra67","journal-title":"Sci Signal"},{"issue":"7","key":"5424_CR57","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","volume":"36","author":"RW Mahley","year":"2016","unstructured":"Mahley RW (2016) Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler Thromb Vasc Biol 36(7):1305\u20131315","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"5424_CR58","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.cub.2006.10.029","volume":"16","author":"U Beffert","year":"2006","unstructured":"Beffert U, Nematollah Farsian F, Masiulis I, Hammer RE, Yoon SO, Giehl KM et al (2006) ApoE receptor 2 controls neuronal survival in the adult brain. Curr Biol 16(24):2446\u20132452","journal-title":"Curr Biol"},{"issue":"3","key":"5424_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0304-3940(02)00942-4","volume":"332","author":"SL Ma","year":"2002","unstructured":"Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J et al (2002) Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer\u2019s disease. Neurosci Lett 332(3):216\u2013218","journal-title":"Neurosci Lett"},{"issue":"6","key":"5424_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0962-8924(02)02282-1","volume":"12","author":"A Nykjaer","year":"2002","unstructured":"Nykjaer A, Willnow TE (2002) The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol 12(6):273\u2013280","journal-title":"Trends Cell Biol"},{"issue":"3","key":"5424_CR61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1152\/physrev.00033.2007","volume":"88","author":"AP Lillis","year":"2008","unstructured":"Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK (2008) LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88(3):887\u2013918","journal-title":"Physiol Rev"},{"key":"5424_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070948","author":"S Petralla","year":"2024","unstructured":"Petralla S, Panayotova M, Franchina E, Fricker G, Puris E (2024) Low-density lipoprotein receptor-related protein 1 as a potential therapeutic target in Alzheimer\u2019s disease. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16070948","journal-title":"Pharmaceutics"},{"issue":"4","key":"5424_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04237-x","volume":"79","author":"AD Mazura","year":"2022","unstructured":"Mazura AD, Ohler A, Storck SE, Kurtyka M, Scharfenberg F, Weggen S et al (2022) PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier. Cell Mol Life Sci 79(4):212","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5424_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck SE, Meister S, Nahrath J, Mei\u00dfner JN, Schubert N, Di Spiezio A et al (2016) Endothelial LRP1 transports amyloid-\u03b2(1\u201342) across the blood-brain barrier. J Clin Invest 126(1):123\u2013136","journal-title":"J Clin Invest"},{"key":"5424_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119310","volume":"273","author":"SA Abuelezz","year":"2021","unstructured":"Abuelezz SA, Hendawy N (2021) HMGB1\/RAGE\/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci 273:119310","journal-title":"Life Sci"},{"issue":"5","key":"5424_CR66","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G (2009) Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10(5):333\u2013344","journal-title":"Nat Rev Neurosci"},{"key":"5424_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041268","author":"AD Mazura","year":"2023","unstructured":"Mazura AD, Pietrzik CU (2023) Endocrine regulation of microvascular receptor-mediated transcytosis and its therapeutic opportunities: insights by PCSK9-mediated regulation. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041268","journal-title":"Pharmaceutics"},{"issue":"5","key":"5424_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG (2013) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE 8(5):e64145","journal-title":"PLoS ONE"},{"issue":"10","key":"5424_CR69","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/NEN.0b013e3181f46e25","volume":"69","author":"GD Silverberg","year":"2010","unstructured":"Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG et al (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69(10):1034\u20131043","journal-title":"J Neuropathol Exp Neurol"},{"key":"5424_CR70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29595","author":"J Robert","year":"2017","unstructured":"Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A et al (2017) Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife. https:\/\/doi.org\/10.7554\/eLife.29595","journal-title":"Elife"},{"issue":"19","key":"5424_CR71","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A et al (2013) ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proc Natl Acad Sci U S A 110(19):E1807-1816","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5424_CR72","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","volume":"253","author":"N Ferri","year":"2016","unstructured":"Ferri N, Marchian\u00f2 S, Tibolla G, Baetta R, Dhyani A, Ruscica M et al (2016) PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis 253:214\u2013224","journal-title":"Atherosclerosis"},{"issue":"42","key":"5424_CR73","doi-asserted-by":"publisher","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K et al (2009) Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 284(42):28856\u201328864","journal-title":"J Biol Chem"},{"key":"5424_CR74","doi-asserted-by":"publisher","first-page":"103390","DOI":"10.1016\/j.mcn.2019.103390","volume":"99","author":"CC Gali","year":"2019","unstructured":"Gali CC, Fanaee-Danesh E, Zandl-Lang M, Albrecher NM, Tam-Amersdorfer C, Stracke A et al (2019) Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-\u03b2 in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci 99:103390","journal-title":"Mol Cell Neurosci"},{"issue":"7","key":"5424_CR75","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s11095-006-0208-7","volume":"23","author":"C Tamaki","year":"2006","unstructured":"Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C et al (2006) Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23(7):1407\u20131416","journal-title":"Pharm Res"},{"issue":"1","key":"5424_CR76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13578-022-00807-5","volume":"12","author":"J Li","year":"2022","unstructured":"Li J, Li M, Ge Y, Chen J, Ma J, Wang C et al (2022) \u0392-amyloid protein induces mitophagy-dependent ferroptosis through the CD36\/PINK\/PARKIN pathway leading to blood-brain barrier destruction in Alzheimer\u2019s disease. Cell Biosci 12(1):69","journal-title":"Cell Biosci"},{"issue":"33","key":"5424_CR77","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice. J Neurosci 28(33):8354\u20138360","journal-title":"J Neurosci"},{"key":"5424_CR78","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fnagi.2019.00120","volume":"11","author":"MP Adorni","year":"2019","unstructured":"Adorni MP, Ruscica M, Ferri N, Bernini F, Zimetti F (2019) Proprotein convertase subtilisin\/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer\u2019s disease. Front Aging Neurosci 11:120","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"5424_CR79","first-page":"108","volume":"12","author":"SP Pezeshki","year":"2023","unstructured":"Pezeshki SP, Karimi Darabi M, Nazeri Z, Sarkaki A, Rashidi M, Babaahmadi-Rezaei H et al (2023) Mesenchymal stem cells therapy led to the improvement of spatial memory in rats with Alzheimer\u2019s disease through changing the expression of LncRNA TUSC7\/ miR-449a\/ PPAR\u03b3 and CD36 genes in the brain tissue. Int J Mol Cell Med 12(2):108\u2013119","journal-title":"Int J Mol Cell Med"},{"issue":"72","key":"5424_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.272re3","volume":"2","author":"RL Silverstein","year":"2009","unstructured":"Silverstein RL, Febbraio M (2009) CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2(72):re3","journal-title":"Sci Signal"},{"key":"5424_CR81","doi-asserted-by":"crossref","unstructured":"Zhang H, Xu Q, Zhao Y, He N, Ren Z, Xiang Q,\u00a0Tang Z, Liu L (2025) A novel perspective on PCSK9 in Alzheimer\u2019s disease: a focus on amyloid beta. Curr Med Chem 32(22):4516\u20134528","DOI":"10.2174\/0109298673269288231123095215"},{"issue":"6","key":"5424_CR82","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/alz.12468","volume":"18","author":"E Horgusluoglu","year":"2022","unstructured":"Horgusluoglu E, Neff R, Song WM, Wang M, Wang Q, Arnold M et al (2022) Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer\u2019s disease. Alzheimers Dement 18(6):1260\u20131278","journal-title":"Alzheimers Dement"},{"issue":"12","key":"5424_CR83","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41588-022-01208-7","volume":"54","author":"H Holstege","year":"2022","unstructured":"Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D et al (2022) Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer\u2019s disease. Nat Genet 54(12):1786\u20131794","journal-title":"Nat Genet"},{"key":"5424_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","volume":"256","author":"MP Adorni","year":"2017","unstructured":"Adorni MP, Cipollari E, Favari E, Zanotti I, Zimetti F, Corsini A et al (2017) Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis 256:1\u20136","journal-title":"Atherosclerosis"},{"issue":"2","key":"5424_CR85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.gene.2012.09.009","volume":"510","author":"M Jiang","year":"2012","unstructured":"Jiang M, Lv L, Wang H, Yang X, Ji H, Zhou F et al (2012) Meta-analysis on association between the ATP-binding cassette transporter A1 gene (ABCA1) and Alzheimer\u2019s disease. Gene 510(2):147\u2013153","journal-title":"Gene"},{"issue":"2","key":"5424_CR86","first-page":"671","volume":"118","author":"SE Wahrle","year":"2008","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A et al (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118(2):671\u2013682","journal-title":"J Clin Invest"},{"issue":"52","key":"5424_CR87","doi-asserted-by":"publisher","first-page":"43243","DOI":"10.1074\/jbc.M508781200","volume":"280","author":"V Hirsch-Reinshagen","year":"2005","unstructured":"Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA et al (2005) The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280(52):43243\u201343256","journal-title":"J Biol Chem"},{"issue":"39","key":"5424_CR88","doi-asserted-by":"publisher","first-page":"40987","DOI":"10.1074\/jbc.M407963200","volume":"279","author":"SE Wahrle","year":"2004","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD et al (2004) ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279(39):40987\u201340993","journal-title":"J Biol Chem"},{"key":"5424_CR89","doi-asserted-by":"publisher","DOI":"10.6064\/2012\/927352","volume":"2012","author":"N Ferri","year":"2012","unstructured":"Ferri N (2012) Proprotein convertase subtilisin\/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica 2012:927352","journal-title":"Scientifica"},{"issue":"5","key":"5424_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11745-014-3895-6","volume":"49","author":"YQ Chen","year":"2014","unstructured":"Chen YQ, Troutt JS, Konrad RJ (2014) PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids 49(5):445\u2013455","journal-title":"Lipids"},{"issue":"4","key":"5424_CR91","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3233\/JAD-170993","volume":"62","author":"H Courtemanche","year":"2018","unstructured":"Courtemanche H, Bigot E, Pichelin M, Guyomarch B, Boutoleau-Bretonni\u00e8re C, Le May C et al (2018) PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer\u2019s disease. J Alzheimers Dis 62(4):1519\u20131525","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5424_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JAD-160411","volume":"55","author":"F Zimetti","year":"2017","unstructured":"Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I et al (2017) Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis: JAD 55(1):315\u2013320","journal-title":"J Alzheimer's Dis: JAD"},{"issue":"8","key":"5424_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220254","volume":"14","author":"C Picard","year":"2019","unstructured":"Picard C, Poirier A, B\u00e9langer S, Labont\u00e9 A, Auld D, Poirier J (2019) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: a genetic and proteomic multi-cohort study. PLoS ONE 14(8):e0220254","journal-title":"PLoS ONE"},{"issue":"12","key":"5424_CR94","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264\u20131272","journal-title":"N Engl J Med"},{"issue":"9","key":"5424_CR95","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/archneur.1994.00540210060013","volume":"51","author":"D Galasko","year":"1994","unstructured":"Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R et al (1994) Clinical-neuropathological correlations in Alzheimer\u2019s disease and related dementias. Arch Neurol 51(9):888\u2013895","journal-title":"Arch Neurol"},{"issue":"2","key":"5424_CR96","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0891988718764330","volume":"31","author":"M Paquette","year":"2018","unstructured":"Paquette M, Saavedra YGL, Poirier J, Th\u00e9roux L, Dea D, Baass A et al (2018) Loss-of-function PCSK9 mutations are not associated with Alzheimer disease. J Geriatr Psychiatry Neurol 31(2):90\u201396","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"4","key":"5424_CR97","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00041444-200512000-00004","volume":"15","author":"N Shibata","year":"2005","unstructured":"Shibata N, Ohnuma T, Higashi S, Higashi M, Usui C, Ohkubo T et al (2005) No genetic association between PCSK9 polymorphisms and Alzheimer\u2019s disease and plasma cholesterol level in Japanese patients. Psychiatr Genet 15(4):239","journal-title":"Psychiatr Genet"},{"issue":"10","key":"5424_CR98","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/hmg\/ddq079","volume":"19","author":"CA Reynolds","year":"2010","unstructured":"Reynolds CA, Hong MG, Eriksson UK, Blennow K, Wiklund F, Johansson B et al (2010) Analysis of lipid pathway genes indicates association of sequence variation near SREBF1\/TOM1L2\/ATPAF2 with dementia risk. Hum Mol Genet 19(10):2068\u20132078","journal-title":"Hum Mol Genet"},{"issue":"8","key":"5424_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3346","volume":"23","author":"N Shyamala","year":"2021","unstructured":"Shyamala N, Gundapaneni KK, Galimudi RK, Tupurani MA, Padala C, Puranam K et al (2021) PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients. J Gene Med 23(8):e3346","journal-title":"J Gene Med"},{"issue":"8003","key":"5424_CR100","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","volume":"627","author":"MA Cappelluti","year":"2024","unstructured":"Cappelluti MA, Mollica Poeta V, Valsoni S, Quarato P, Merlin S, Merelli I et al (2024) Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 627(8003):416\u2013423","journal-title":"Nature"},{"issue":"4","key":"5424_CR101","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41591-025-03508-x","volume":"31","author":"F Tremblay","year":"2025","unstructured":"Tremblay F, Xiong Q, Shah SS, Ko CW, Kelly K, Morrison MS et al (2025) A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nat Med 31(4):1329\u20131338","journal-title":"Nat Med"},{"issue":"6","key":"5424_CR102","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","volume":"18","author":"MV Holmes","year":"2021","unstructured":"Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G (2021) Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol 18(6):435\u2013453","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"5424_CR103","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, Asselbergs FW, Freitag DF, Patel RS et al (2020) Genetic drug target validation using Mendelian randomisation. Nat Commun 11(1):3255","journal-title":"Nat Commun"},{"issue":"3","key":"5424_CR104","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/gte.2008.0013","volume":"12","author":"F Sirois","year":"2008","unstructured":"Sirois F, Gbeha E, Sanni A, Chretien M, Labuda D, Mbikay M (2008) Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population. Genet Test 12(3):377\u2013380","journal-title":"Genet Test"},{"issue":"1","key":"5424_CR105","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25642","volume":"87","author":"DM Williams","year":"2020","unstructured":"Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD (2020) Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. Ann Neurol 87(1):30\u201339","journal-title":"Ann Neurol"},{"key":"5424_CR106","doi-asserted-by":"publisher","first-page":"j1648","DOI":"10.1136\/bmj.j1648","volume":"357","author":"M Benn","year":"2017","unstructured":"Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybj\u00e6rg-Hansen A (2017) Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer\u2019s disease and Parkinson\u2019s disease: Mendelian randomisation study. BMJ (Clin Res ed) 357:j1648","journal-title":"BMJ (Clin Res ed)"},{"issue":"5","key":"5424_CR107","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","volume":"24","author":"I Bj\u00f6rkhem","year":"2004","unstructured":"Bj\u00f6rkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24(5):806\u2013815","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5424_CR108","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fneur.2019.01152","volume":"10","author":"M Corraliza-Gomez","year":"2019","unstructured":"Corraliza-Gomez M, Sanchez D, Ganfornina MD (2019) Lipid-binding proteins in brain health and disease. Front Neurol 10:1152","journal-title":"Front Neurol"},{"issue":"16","key":"5424_CR109","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"issue":"16","key":"5424_CR110","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500\u20131509","journal-title":"N Engl J Med"},{"issue":"16","key":"5424_CR111","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F et al (2017) Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376(16):1527\u20131539","journal-title":"N Engl J Med"},{"issue":"2","key":"5424_CR112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3892\/br.2013.213","volume":"2","author":"Q Wu","year":"2014","unstructured":"Wu Q, Tang ZH, Peng J, Liao L, Pan LH, Wu CY et al (2014) The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer\u2019s disease progression (Review). Biomed Rep 2(2):167\u2013171","journal-title":"Biomed Rep"},{"issue":"9","key":"5424_CR113","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2008.132","volume":"9","author":"MC Jonas","year":"2008","unstructured":"Jonas MC, Costantini C, Puglielli L (2008) PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep 9(9):916\u2013922","journal-title":"EMBO Rep"},{"issue":"2","key":"5424_CR114","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010838","volume":"8","author":"N Apaijai","year":"2019","unstructured":"Apaijai N, Moisescu DM, Palee S, McSweeney CM, Saiyasit N, Maneechote C et al (2019) Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation. J Am Heart Assoc 8(2):e010838","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"5424_CR115","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbalip.2017.05.002","volume":"1862","author":"T Fu","year":"2017","unstructured":"Fu T, Guan Y, Xu J, Wang Y (2017) APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. Biochim Biophys Acta 1862(9):883\u2013889","journal-title":"Biochim Biophys Acta"},{"key":"5424_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020093","author":"DE Kim","year":"2020","unstructured":"Kim DE, Priefer R (2020) Therapeutic potential of direct clearance of the amyloid-\u03b2 in Alzheimer\u2019s disease. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci10020093","journal-title":"Brain Sci"},{"issue":"3","key":"5424_CR117","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-161136","volume":"57","author":"LS Liu","year":"2017","unstructured":"Liu LS, Bai XQ, Gao Y, Wu Q, Ren Z, Li Q et al (2017) PCSK9 promotes oxLDL-induced PC12 cell apoptosis through the Bcl-2\/Bax-Caspase 9\/3 signaling pathway. J Alzheimer\u2019s Dis: JAD 57(3):723\u2013734","journal-title":"J Alzheimer's Dis: JAD"},{"key":"5424_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012192","author":"B Papotti","year":"2022","unstructured":"Papotti B, Adorni MP, Marchi C, Zimetti F, Ronda N, Panighel G et al (2022) PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232012192","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5424_CR119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JAD-132228","volume":"41","author":"J de Oliveira","year":"2014","unstructured":"de Oliveira J, Moreira EL, dos Santos DB, Piermartiri TC, Dutra RC, Pinton S et al (2014) Increased susceptibility to amyloid-\u03b2-induced neurotoxicity in mice lacking the low-density lipoprotein receptor. J Alzheimer\u2019s Dis: JAD 41(1):43\u201360","journal-title":"J Alzheimer's Dis: JAD"},{"issue":"10","key":"5424_CR120","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1042\/CS20100094","volume":"119","author":"R Altman","year":"2010","unstructured":"Altman R, Rutledge JC (2010) The vascular contribution to Alzheimer\u2019s disease. Clin Sci 119(10):407\u2013421","journal-title":"Clin Sci"},{"issue":"7","key":"5424_CR121","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","volume":"76","author":"TS Wingo","year":"2019","unstructured":"Wingo TS, Cutler DJ, Wingo AP, Le NA, Rabinovici GD, Miller BL et al (2019) Association of early-onset Alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB. JAMA Neurol 76(7):809\u2013817","journal-title":"JAMA Neurol"},{"key":"5424_CR122","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s Dement (New York, N Y) 4:575\u2013590","journal-title":"Alzheimer's Dement (New York, N Y)"},{"issue":"2","key":"5424_CR123","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ni.1836","volume":"11","author":"CR Stewart","year":"2010","unstructured":"Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A et al (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155\u2013161","journal-title":"Nat Immunol"},{"issue":"4","key":"5424_CR124","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","volume":"30","author":"Z Tang","year":"2012","unstructured":"Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C et al (2012) PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages. Int J Mol Med 30(4):931\u2013938","journal-title":"Int J Mol Med"},{"issue":"5","key":"5424_CR125","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11064-019-02748-x","volume":"44","author":"J Zhou","year":"2019","unstructured":"Zhou J, Yu W, Zhang M, Tian X, Li Y, L\u00fc Y (2019) Imbalance of microglial TLR4\/TREM2 in LPS-treated APP\/PS1 transgenic mice: a potential link between Alzheimer\u2019s disease and systemic inflammation. Neurochem Res 44(5):1138\u20131151","journal-title":"Neurochem Res"},{"key":"5424_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020383","author":"YN Paudel","year":"2020","unstructured":"Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, Shaikh MF (2020) Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s disease (AD): from risk factors to therapeutic targeting. Cells. https:\/\/doi.org\/10.3390\/cells9020383","journal-title":"Cells"},{"key":"5424_CR127","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00299","author":"LM Park","year":"2024","unstructured":"Park LM, Pacher P, Lohoff FW (2024) Targeting oxidative stress in neurodegenerative disorders: a novel role for PCSK9 inhibition? ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.4c00299","journal-title":"ACS Chem Neurosci"},{"key":"5424_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108470","volume":"689","author":"B Arunsak","year":"2020","unstructured":"Arunsak B, Pratchayasakul W, Amput P, Chattipakorn K, Tosukhowong T, Kerdphoo S et al (2020) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Arch Biochem Biophys 689:108470","journal-title":"Arch Biochem Biophys"},{"issue":"1\u20132","key":"5424_CR129","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11481-023-10060-3","volume":"18","author":"N Hendawy","year":"2023","unstructured":"Hendawy N, Salaheldin TH, Abuelezz SA (2023) PCSK9 inhibition reduces depressive like behavior in CUMS-exposed rats: highlights on HMGB1\/RAGE\/TLR4 pathway, NLRP3 inflammasome complex and IDO-1. J Neuroimmune Pharmacol 18(1\u20132):195\u2013207","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"5424_CR130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2009.08.015","volume":"123","author":"D Zamb\u00f3n","year":"2010","unstructured":"Zamb\u00f3n D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-S\u00e1nchez F et al (2010) Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123(3):267\u2013274","journal-title":"Am J Med"},{"issue":"2","key":"5424_CR131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","volume":"71","author":"B Reed","year":"2014","unstructured":"Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W (2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71(2):195\u2013200","journal-title":"JAMA Neurol"},{"issue":"4","key":"5424_CR132","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"L Da Dalt","year":"2019","unstructured":"Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E et al (2019) PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J 40(4):357\u2013368","journal-title":"Eur Heart J"},{"key":"5424_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104707","volume":"135","author":"A Akhtar","year":"2020","unstructured":"Akhtar A, Sah SP (2020) Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer\u2019s disease. Neurochem Int 135:104707","journal-title":"Neurochem Int"},{"issue":"1","key":"5424_CR134","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","volume":"238","author":"I Giunzioni","year":"2016","unstructured":"Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y et al (2016) Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol 238(1):52\u201362","journal-title":"J Pathol"},{"issue":"7","key":"5424_CR135","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","volume":"291","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J et al (2016) Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem 291(7):3508\u20133519","journal-title":"J Biol Chem"},{"issue":"2","key":"5424_CR136","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","volume":"234","author":"S Li","year":"2014","unstructured":"Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J et al (2014) Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 234(2):441\u2013445","journal-title":"Atherosclerosis"},{"issue":"5","key":"5424_CR137","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","volume":"8","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J et al (2014) Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 8(5):494\u2013500","journal-title":"J Clin Lipidol"},{"issue":"17","key":"5424_CR138","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/2047487318792626","volume":"25","author":"MG Zenti","year":"2018","unstructured":"Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A et al (2018) From lipoprotein apheresis to proprotein convertase subtilisin\/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 25(17):1843\u20131851","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"5424_CR139","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L et al (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24(8):1454\u20131459","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"5424_CR140","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/exnr.1995.1025","volume":"133","author":"G Smale","year":"1995","unstructured":"Smale G, Nichols NR, Brady DR, Finch CE, Horton WE Jr (1995) Evidence for apoptotic cell death in Alzheimer\u2019s disease. Exp Neurol 133(2):225\u2013230","journal-title":"Exp Neurol"},{"issue":"1","key":"5424_CR141","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/A:1009625323388","volume":"5","author":"S Shimohama","year":"2000","unstructured":"Shimohama S (2000) Apoptosis in Alzheimer\u2019s disease\u2013an update. Apoptosis 5(1):9\u201316","journal-title":"Apoptosis"},{"issue":"11","key":"5424_CR142","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/cyto.a.20346","volume":"69","author":"B Bingham","year":"2006","unstructured":"Bingham B, Shen R, Kotnis S, Lo CF, Ozenberger BA, Ghosh N et al (2006) Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase. Cytometry A 69(11):1123\u20131131","journal-title":"Cytometry A"},{"issue":"12","key":"5424_CR143","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrcardio.2013.163","volume":"10","author":"M Cully","year":"2013","unstructured":"Cully M (2013) Dyslipidaemia: RNAi targeting PCSK9 decreases lipid levels in a human trial. Nat Rev Cardiol 10(12):682","journal-title":"Nat Rev Cardiol"},{"issue":"1\u20132","key":"5424_CR144","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","volume":"359","author":"CY Wu","year":"2012","unstructured":"Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS (2012) PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 359(1\u20132):347\u2013358","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"5424_CR145","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3892\/mmr.2016.6055","volume":"15","author":"XS Zhao","year":"2017","unstructured":"Zhao XS, Wu Q, Peng J, Pan LH, Ren Z, Liu HT et al (2017) Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-\/-) mice may be associated with increased PCSK9 expression. Mol Med Rep 15(2):712\u2013718","journal-title":"Mol Med Rep"},{"issue":"3","key":"5424_CR146","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","volume":"98","author":"S Poirier","year":"2006","unstructured":"Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, Baranowski D et al (2006) Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system. J Neurochem 98(3):838\u2013850","journal-title":"J Neurochem"},{"issue":"11","key":"5424_CR147","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","volume":"44","author":"KN Maxwell","year":"2003","unstructured":"Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 44(11):2109\u20132119","journal-title":"J Lipid Res"},{"issue":"1","key":"5424_CR148","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.16586","volume":"61","author":"L Gence","year":"2025","unstructured":"Gence L, Morello E, Rastegar S, Apalama ML, Meilhac O, Bascands JL et al (2025) Gene expression patterns of the LDL receptor and its inhibitor Pcsk9 in the adult zebrafish brain suggest a possible role in neurogenesis. Eur J Neurosci 61(1):e16586","journal-title":"Eur J Neurosci"},{"key":"5424_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105155","volume":"149","author":"AS Bell","year":"2023","unstructured":"Bell AS, Wagner J, Rosoff DB, Lohoff FW (2023) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the central nervous system. Neurosci Biobehav Rev 149:105155","journal-title":"Neurosci Biobehav Rev"},{"issue":"12","key":"5424_CR150","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1194\/jlr.R075630","volume":"58","author":"TY Chang","year":"2017","unstructured":"Chang TY, Yamauchi Y, Hasan MT, Chang C (2017) Cellular cholesterol homeostasis and Alzheimer\u2019s disease. J Lipid Res 58(12):2239\u20132254","journal-title":"J Lipid Res"},{"issue":"4","key":"5424_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109889","volume":"37","author":"SA Berghoff","year":"2021","unstructured":"Berghoff SA, Spieth L, Sun T, Hosang L, Depp C, Sasmita AO et al (2021) Neuronal cholesterol synthesis is essential for repair of chronically demyelinated lesions in mice. Cell Rep 37(4):109889","journal-title":"Cell Rep"},{"issue":"8","key":"5424_CR152","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/hipo.20548","volume":"19","author":"L Fester","year":"2009","unstructured":"Fester L, Zhou L, B\u00fctow A, Huber C, von Lossow R, Prange-Kiel J et al (2009) Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 19(8):692\u2013705","journal-title":"Hippocampus"},{"issue":"7964","key":"5424_CR153","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-023-06120-6","volume":"618","author":"C Depp","year":"2023","unstructured":"Depp C, Sun T, Sasmita AO, Spieth L, Berghoff SA, Nazarenko T et al (2023) Myelin dysfunction drives amyloid-\u03b2 deposition in models of Alzheimer\u2019s disease. Nature 618(7964):349\u2013357","journal-title":"Nature"},{"issue":"3","key":"5424_CR154","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1582-4934.2007.00054.x","volume":"11","author":"PC Reid","year":"2007","unstructured":"Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer\u2019s disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11(3):383\u2013392","journal-title":"J Cell Mol Med"},{"key":"5424_CR155","doi-asserted-by":"publisher","first-page":"180.e181","DOI":"10.1016\/j.neurobiolaging.2018.01.018","volume":"66","author":"C Picard","year":"2018","unstructured":"Picard C, Julien C, Frappier J, Miron J, Th\u00e9roux L, Dea D et al (2018) Alterations in cholesterol metabolism-related genes in sporadic Alzheimer\u2019s disease. Neurobiol Aging 66:180.e181-180.e189","journal-title":"Neurobiol Aging"},{"key":"5424_CR156","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jns.2004.11.036","volume":"229\u2013230","author":"AR Koudinov","year":"2005","unstructured":"Koudinov AR, Koudinova NV (2005) Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 229\u2013230:233\u2013240","journal-title":"J Neurol Sci"},{"issue":"1","key":"5424_CR157","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2008.10.027","volume":"203","author":"T Fasano","year":"2009","unstructured":"Fasano T, Sun XM, Patel DD, Soutar AK (2009) Degradation of LDLR protein mediated by \u201cgain of function\u201d PCSK9 mutants in normal and ARH cells. Atherosclerosis 203(1):166\u2013171","journal-title":"Atherosclerosis"},{"issue":"8","key":"5424_CR158","first-page":"675","volume":"126","author":"L Zhang","year":"2016","unstructured":"Zhang L, Song K, Zhu M, Shi J, Zhang H, Xu L et al (2016) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int J Neurosci 126(8):675\u2013680","journal-title":"Int J Neurosci"},{"key":"5424_CR159","first-page":"1135","volume":"7","author":"S Poirier","year":"2013","unstructured":"Poirier S, Mayer G (2013) The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 7:1135\u20131148","journal-title":"Drug Des Devel Ther"},{"key":"5424_CR160","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cca.2016.02.024","volume":"456","author":"Z Xue-Shan","year":"2016","unstructured":"Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T et al (2016) Imbalanced cholesterol metabolism in Alzheimer\u2019s disease. Clin Chim Acta 456:107\u2013114","journal-title":"Clin Chim Acta"},{"issue":"12","key":"5424_CR161","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.jacc.2020.01.033","volume":"75","author":"SA Burnap","year":"2020","unstructured":"Burnap SA, Joshi A, Tsimikas S, Fern\u00e1ndez-Hernando C, Kiechl S, Berry SE et al (2020) High-density lipoproteins are the main carriers of PCSK9 in the circulation. J Am Coll Cardiol 75(12):1495\u20131497","journal-title":"J Am Coll Cardiol"},{"key":"5424_CR162","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fneur.2019.00441","volume":"10","author":"HS Chung","year":"2019","unstructured":"Chung HS, Lee JS, Kim JA, Roh E, Lee YB, Hong SH et al (2019) Variability in total cholesterol concentration is associated with the risk of dementia: a nationwide population-based cohort study. Front Neurol 10:441","journal-title":"Front Neurol"},{"key":"5424_CR163","unstructured":"(2017) Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ (Clinical research ed); 357:j3170"},{"issue":"3","key":"5424_CR164","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.mam.2009.02.001","volume":"30","author":"I Bj\u00f6rkhem","year":"2009","unstructured":"Bj\u00f6rkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative diseases. Mol Aspects Med 30(3):171\u2013179","journal-title":"Mol Aspects Med"},{"issue":"5","key":"5424_CR165","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","volume":"21","author":"HG Lee","year":"2022","unstructured":"Lee HG, Wheeler MA, Quintana FJ (2022) Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov 21(5):339\u2013358","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5424_CR166","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbalip.2012.09.007","volume":"1831","author":"J Chen","year":"2013","unstructured":"Chen J, Zhang X, Kusumo H, Costa LG, Guizzetti M (2013) Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis. Biochim Biophys Acta 1831(2):263\u2013275","journal-title":"Biochim Biophys Acta"},{"key":"5424_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106505","volume":"196","author":"B Tong","year":"2024","unstructured":"Tong B, Ba Y, Li Z, Yang C, Su K, Qi H et al (2024) Targeting dysregulated lipid metabolism for the treatment of Alzheimer\u2019s disease and Parkinson\u2019s disease: current advancements and future prospects. Neurobiol Dis 196:106505","journal-title":"Neurobiol Dis"},{"issue":"1","key":"5424_CR168","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacl.2009.11.003","volume":"4","author":"RC Block","year":"2010","unstructured":"Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 4(1):17\u201323","journal-title":"J Clin Lipidol"},{"issue":"5","key":"5424_CR169","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrn3012","volume":"12","author":"G Di Paolo","year":"2011","unstructured":"Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer\u2019s disease: cholesterol and beyond. Nat Rev Neurosci 12(5):284\u2013296","journal-title":"Nat Rev Neurosci"},{"key":"5424_CR170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102191118","author":"H Wang","year":"2021","unstructured":"Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB (2021) Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2102191118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"5424_CR171","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet 45(12):1452\u20131458","journal-title":"Nat Genet"},{"key":"5424_CR172","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.gene.2016.10.022","volume":"597","author":"HK Dong","year":"2017","unstructured":"Dong HK, Gim JA, Yeo SH, Kim HS (2017) Integrated late onset Alzheimer\u2019s disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives. Gene 597:10\u201316","journal-title":"Gene"},{"issue":"3","key":"5424_CR173","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12031-016-0839-z","volume":"60","author":"L Mahoney-Sanchez","year":"2016","unstructured":"Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S (2016) The complex role of apolipoprotein E in Alzheimer\u2019s disease: an overview and update. J Mol Neurosci: MN 60(3):325\u2013335","journal-title":"J Mol Neurosci: MN"},{"issue":"9","key":"5424_CR174","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","volume":"7","author":"AJ Cupido","year":"2022","unstructured":"Cupido AJ, Reeskamp LF, Hingorani AD, Finan C, Asselbergs FW, Hovingh GK et al (2022) Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study. JAMA Cardiol 7(9):955\u2013964","journal-title":"JAMA Cardiol"},{"issue":"12","key":"5424_CR175","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM et al (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5(12):941\u2013950","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5424_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810418","author":"LA Hsu","year":"2022","unstructured":"Hsu LA, Teng MS, Wu S, Chou HH, Ko YL (2022) Common and rare PCSK9 variants associated with low-density lipoprotein cholesterol levels and the risk of diabetes mellitus: a Mendelian randomization study. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231810418","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5424_CR177","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","volume":"24","author":"S Carugo","year":"2022","unstructured":"Carugo S, Sirtori CR, Corsini A, Tokgozoglu L, Ruscica M (2022) PCSK9 inhibition and risk of diabetes: should we worry? Curr Atheroscler Rep 24(12):995\u20131004","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"5424_CR178","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","volume":"584","author":"M Mbikay","year":"2010","unstructured":"Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T et al (2010) PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 584(4):701\u2013706","journal-title":"FEBS Lett"},{"issue":"3","key":"5424_CR179","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","volume":"26","author":"B Cariou","year":"2015","unstructured":"Cariou B, Si-Tayeb K, Le May C (2015) Role of PCSK9 beyond liver involvement. Curr Opin Lipidol 26(3):155\u2013161","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"5424_CR180","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/1753-0407.12139","volume":"7","author":"M Mbikay","year":"2015","unstructured":"Mbikay M, Sirois F, Gyamera-Acheampong C, Wang GS, Rippstein P, Chen A et al (2015) Variable effects of gender and western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL\/6 mice CSK9PC57BL\/6. J Diabetes 7(1):74\u201384","journal-title":"J Diabetes"},{"issue":"8","key":"5424_CR181","doi-asserted-by":"publisher","first-page":"158968","DOI":"10.1016\/j.bbalip.2021.158968","volume":"1866","author":"ML Peyot","year":"2021","unstructured":"Peyot ML, Roubtsova A, Lussier R, Chamberland A, Essalmani R, Murthy Madiraju SR et al (2021) Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice. Biochim Biophys Acta 1866(8):158968","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"5424_CR182","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.2337\/db07-0056","volume":"56","author":"M Hao","year":"2007","unstructured":"Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56(9):2328\u20132338","journal-title":"Diabetes"},{"issue":"20","key":"5424_CR183","doi-asserted-by":"publisher","first-page":"18368","DOI":"10.1074\/jbc.M300102200","volume":"278","author":"ME Roehrich","year":"2003","unstructured":"Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S et al (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 278(20):18368\u201318375","journal-title":"J Biol Chem"},{"issue":"6","key":"5424_CR184","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","volume":"22","author":"AA Momtazi","year":"2017","unstructured":"Momtazi AA, Banach M, Pirro M, Stein EA, Sahebkar A (2017) PCSK9 and diabetes: is there a link? Drug Discov Today 22(6):883\u2013895","journal-title":"Drug Discov Today"},{"issue":"6","key":"5424_CR185","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jacl.2015.08.005","volume":"9","author":"YGL Saavedra","year":"2015","unstructured":"Saavedra YGL, Dufour R, Baass A (2015) Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes\/diabetes risk. J Clin Lipidol 9(6):786-793.e781","journal-title":"J Clin Lipidol"},{"issue":"1","key":"5424_CR186","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12872-019-1187-z","volume":"19","author":"AF Schmidt","year":"2019","unstructured":"Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G et al (2019) Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord 19(1):240","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"5424_CR187","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM et al (2017) PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 5(2):97\u2013105","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5424_CR188","first-page":"f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ (Clin Res ed) 346:f2610","journal-title":"BMJ (Clin Res ed)"},{"issue":"9716","key":"5424_CR189","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735\u2013742","journal-title":"Lancet"},{"key":"5424_CR190","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2014.07.004","volume":"145","author":"AD Marais","year":"2015","unstructured":"Marais AD, Kim JB, Wasserman SM, Lambert G (2015) PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther 145:58\u201366","journal-title":"Pharmacol Ther"},{"key":"5424_CR191","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN et al (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 13:123","journal-title":"BMC Med"},{"issue":"1","key":"5424_CR192","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40119-020-00163-w","volume":"9","author":"RHM Furtado","year":"2020","unstructured":"Furtado RHM, Giugliano RP (2020) What lessons have we learned and what remains to be clarified for PCSK9 inhibitors? A review of FOURIER and ODYSSEY outcomes trials. Cardiol Ther 9(1):59\u201373","journal-title":"Cardiol Ther"},{"issue":"2","key":"5424_CR193","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","volume":"64","author":"RA Whitmer","year":"2005","unstructured":"Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64(2):277\u2013281","journal-title":"Neurology"},{"issue":"3","key":"5424_CR194","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7326\/0003-4819-137-3-200208060-00006","volume":"137","author":"M Kivipelto","year":"2002","unstructured":"Kivipelto M, Helkala EL, Laakso MP, H\u00e4nninen T, Hallikainen M, Alhainen K et al (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137(3):149\u2013155","journal-title":"Ann Intern Med"},{"issue":"2","key":"5424_CR195","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archneur.59.2.223","volume":"59","author":"K Rockwood","year":"2002","unstructured":"Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R et al (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59(2):223\u2013227","journal-title":"Arch Neurol"},{"issue":"19","key":"5424_CR196","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1001\/jama.2008.683","volume":"300","author":"ST DeKosky","year":"2008","unstructured":"DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA et al (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300(19):2253\u20132262","journal-title":"JAMA"},{"issue":"1","key":"5424_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0237-y","volume":"9","author":"N Geifman","year":"2017","unstructured":"Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ (2017) Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer\u2019s disease. Alzheimers Res Ther 9(1):10","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"5424_CR198","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW et al (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12):956\u2013964","journal-title":"Neurology"},{"issue":"6","key":"5424_CR199","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"M Sano","year":"2011","unstructured":"Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH et al (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77(6):556\u2013563","journal-title":"Neurology"},{"issue":"2","key":"5424_CR200","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4997\/JRCPE.2017.212","volume":"47","author":"S Hadjiphilippou","year":"2017","unstructured":"Hadjiphilippou S, Ray KK (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. J R Coll Physicians Edinb 47(2):153\u2013155","journal-title":"J R Coll Physicians Edinb"},{"issue":"6","key":"5424_CR201","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC et al (2016) The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 37(6):536\u2013545","journal-title":"Eur Heart J"},{"issue":"10106","key":"5424_CR202","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R et al (2017) Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390(10106):1962\u20131971","journal-title":"Lancet"},{"key":"5424_CR203","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.06.913","volume":"331","author":"MJ Janik","year":"2021","unstructured":"Janik MJ, Urbach DV, van Nieuwenhuizen E, Zhao J, Yellin O, Baccara-Dinet MT et al (2021) Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study. Atherosclerosis 331:20\u201327","journal-title":"Atherosclerosis"},{"issue":"12","key":"5424_CR204","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.117.029785","volume":"137","author":"MT Mefford","year":"2018","unstructured":"Mefford MT, Rosenson RS, Cushman M, Farkouh ME, McClure LA, Wadley VG et al (2018) PCSK9 variants, low-density lipoprotein cholesterol, and neurocognitive impairment: reasons for geographic and racial differences in stroke study (REGARDS). Circulation 137(12):1260\u20131269","journal-title":"Circulation"},{"issue":"7","key":"5424_CR205","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E et al (2017) Cognitive function in a randomized trial of evolocumab. N Engl J Med 377(7):633\u2013643","journal-title":"N Engl J Med"},{"issue":"2","key":"5424_CR206","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H et al (2017) Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-a cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 40(2):59\u201365","journal-title":"Clin Cardiol"},{"issue":"22","key":"5424_CR207","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379(22):2097\u20132107","journal-title":"N Engl J Med"},{"issue":"2","key":"5424_CR208","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/ehjqcco\/qcx037","volume":"4","author":"NS Bajaj","year":"2018","unstructured":"Bajaj NS, Patel N, Kalra R, Ahmad A, Venkatraman A, Arora G et al (2018) Neurological effects of proprotein convertase subtilisin\/kexin type 9 inhibitors: direct comparisons. Eur Heart J Qual Care Clin Outcomes 4(2):132\u2013141","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"5424_CR209","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/eurheartj\/ehx661","volume":"39","author":"PD Harvey","year":"2018","unstructured":"Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G et al (2018) No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J 39(5):374\u2013381","journal-title":"Eur Heart J"},{"issue":"1","key":"5424_CR210","doi-asserted-by":"publisher","first-page":"EVIDoa2400112","DOI":"10.1056\/EVIDoa2400112","volume":"4","author":"A Zimerman","year":"2025","unstructured":"Zimerman A, O\u2019Donoghue ML, Ran X, Im K, Ott BR, Mach F et al (2025) Long-term cognitive safety of achieving very low LDL cholesterol with evolocumab. NEJM Evid 4(1):EVIDoa2400112","journal-title":"NEJM Evid"},{"issue":"34","key":"5424_CR211","doi-asserted-by":"publisher","first-page":"23712","DOI":"10.1074\/jbc.M114.556159","volume":"289","author":"AA Saeed","year":"2014","unstructured":"Saeed AA, Genov\u00e9 G, Li T, L\u00fctjohann D, Olin M, Mast N et al (2014) Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. J Biol Chem 289(34):23712\u201323722","journal-title":"J Biol Chem"},{"issue":"4","key":"5424_CR212","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41593-023-01288-6","volume":"26","author":"ZP Chen","year":"2023","unstructured":"Chen ZP, Wang S, Zhao X, Fang W, Wang Z, Ye H et al (2023) Lipid-accumulated reactive astrocytes promote disease progression in epilepsy. Nat Neurosci 26(4):542\u2013554","journal-title":"Nat Neurosci"},{"issue":"1","key":"5424_CR213","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.plipres.2010.09.001","volume":"50","author":"PS Hauser","year":"2011","unstructured":"Hauser PS, Narayanaswami V, Ryan RO (2011) Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res 50(1):62\u201374","journal-title":"Prog Lipid Res"},{"issue":"1","key":"5424_CR214","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K et al (2024) Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther 9(1):13","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"5424_CR215","first-page":"1913","volume":"39","author":"PK Gill","year":"2023","unstructured":"Gill PK, Hegele RA (2023) New biological therapies for low-density lipoprotein cholesterol. Can J Cardiol 39(12):1913\u20131930","journal-title":"Can J Cardiol"},{"key":"5424_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413637","author":"G Testa","year":"2024","unstructured":"Testa G, Giannelli S, Staurenghi E, Cecci R, Floro L, Gamba P et al (2024) The emerging role of PCSK9 in the pathogenesis of Alzheimer\u2019s disease: a possible target for the disease treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252413637","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05424-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05424-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05424-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:03:37Z","timestamp":1764590617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05424-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":216,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5424"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05424-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"231"}}